Engineering actinomycetes for biosynthesis of macrolactone polyketides

Dipesh Dhakal1, Jae Kyung Sohng1,2* and Ramesh Prasad Pandey1,2*

Abstract
Actinobacteria are characterized as the most prominent producer of natural products (NPs) with pharmaceutical importance. The production of NPs from these actinobacteria is associated with particular biosynthetic gene clusters (BGCs) in these microorganisms. The majority of these BGCs include polyketide synthase (PKS) or non-ribosomal peptide synthase (NRPS) or a combination of both PKS and NRPS. Macrolides compounds contain a core macro-lactone ring (aglycone) decorated with diverse functional groups in their chemical structures. The aglycon is generated by megaenzyme polyketide synthases (PKSs) from diverse acyl-CoA as precursor substrates. Further, post-PKS enzymes are responsible for allocating the structural diversity and functional characteristics for their biological activities. Macrolides are biologically important for their uses in therapeutics as antibiotics, anti-tumor agents, immunosuppressants, anti-parasites and many more. Thus, precise genetic/metabolic engineering of actinobacteria along with the application of various chemical/biological approaches have made it plausible for production of macrolides in industrial scale or generation of their novel derivatives with more effective biological properties. In this review, we have discussed versatile approaches for generating a wide range of macrolide structures by engineering the PKS and post-PKS cascades at either enzyme or cellular level in actinobacteria species, either the native or heterologous producer strains.

Keywords: Macrolides, Biosynthesis, Polyketide synthase, Biosynthetic gene clusters, Metabolic engineering, Actinomycetes

Background
Natural products (NPs) from plants or microorganism, native or structurally modified have been utilized for the treatment of infections and ailment of disease conditions [1, 2]. Among all microorganisms, actinobacteria isolated from terrestrial or marine sources are characterized prominent producer of such NPs of pharmaceutical values, such as antibacterial, anticancer agents, anti-parasite, and immunosuppressant [3–5]. Actinobacteria are Gram-positive filamentous bacteria containing a high G+C content. They generally produce mycelium and reproduce by sporulation similar to filamentous fungi. However, they possess prokaryotic nucleoid and peptidoglycan cell wall significantly different from fungi [6]. Hence, the name “actinobacteria” is derived from Greek whereas; “aktis or aktin” meaning “ray” and “mukes” meaning “fungi”. The production of NPs from these actinobacteria is associated with diverse biosynthetic gene clusters (BGCs) present in these microorganisms. Each BGC contain a defined set of genes sufficient for biosynthesis of particular chemical structure. The majority of these BGC include polyketide synthase (PKS) or non-ribosomal peptide synthase (NRPS) or combination of PKS and NRPS.

Macrolides include diversified chemical structures containing a core macro-lactone ring (aglycone) decorated with diverse functional groups, most commonly deoxy-sugars and amino-sugars [7]. They are biologically important for their uses in therapeutics as antibiotics (erythromycin, pikromycin, nargenicin, oleandomycin), anti-tumor agents (epothilone), immunosuppressant (rapamycin, FK506) and anti-parasites (avermectin) (Fig. 1) [8, 9]. Macrolides are categorized into different groups according to the number of atoms in the lactone...
ring, for example, 12-, 14-, 15-, 16-, 17-(ivorenolide B) or 18-(tedanolide C) membered macrolides [10]. They are generally biosynthesized by type I polyketide synthase (PKS) and modified by tailoring enzymes such as glycosyltransferase (GT), methyltransferase (MT) and oxidation enzymes as monooxygenase (MO), cytochrome P450 (CYP450) and oxidoreductase (OR).

The alarmingly increase in drug-resistant bugs or drug-tolerant cancer conditions have vitalized the need for bioactive molecules with new or improved pharmacological properties. Therefore, there is immersing interest on isolation and characterization of novel macrolides. The clinically useful macrolides have been traditionally derived from the screening of natural sources, and still the isolation of novel macrolides and evaluating their bioactivities has been an active area of research [11]. Most of the NPs, including macrolides, exhibit a broad range of pharmacophore, but still, they need to be structurally modified to ameliorate their chemical and biological properties for clinical uses [5, 12]. The total synthesis of macrolide derivative or chemical modification to generate semisynthetic derivative have been an important tool for the development of novel molecules with enhanced pharmacological activities. However, such chemical approaches have limitations as many sites on the macro lactone ring and/or the sugar moiety are not amenable to desired chemical modifications [9, 13]. Another promising approach has been the biological engineering of the production hosts by rational metabolic engineering and synthetic biology tools. The major advantage of such

![Fig. 1 Structures of different macrocyclic compounds with their primary producer strain and potential use of these molecules](image-url)
biological process over chemical approach is cost-effectiveness, environmental friendliness, and easy scale-up possibilities [14, 15].

In this review, the progress on engineering of actinomycetes for deriving novel macrolides by engineering of aglycone biosynthesis and post-PKS tailoring enzymes has been summarized. The front part of the review includes early approaches of precursor-directed biosynthesis and mutasynthesis. Finally, the application of the advanced synthetic biological tools assisted by different “–omics” based approaches for combinatorial biosynthesis of macrolides have been discussed.

Outline of biosynthesis of macrolides

The type I PKS generally consist of multifunctional, multi-modular enzymes with non-iterative catalysis of one cycle of polyketide chain elongation. These enzymes are responsible for successive condensation of activated coenzyme A (CoA) thioesters (most commonly acetyl-, propionyl-, malonyl- or methylmalonyl-CoA) for such polyketide chain elongation. Each module contains a set of functional domains of acyl carrier protein (ACP), acyltransferase (AT), and β-ketoacyl synthase (KS), which are essential for polyketide elongation [16, 17]. The CoAs used as substrate is selected and activated by an acyl transferase (AT) domain and transferred to the 4′-phosphopantetheinylated acyl carrier protein (ACP) domain. The ketosynthase (KS) domain catalyzes the decarboxylative Claisen-like condensation between the substrate and the growing polyketide, to form a carbon–carbon bond between the alpha carbon of the extender unit and the thioester carbonyl of the ACP-bound acyl chain [9, 18, 19]. Besides these minimal domains, additionally, there are β-keto processing domains, keto reductase (KR), dehydratase (DH), and enoyl reductase (ER) that act sequentially to reduce the β-keto group into a fully saturated acyl chain [20]. The synthesized polyketide is off-loaded by thioesterase (TE) domain [21, 22]. Figure 2 shows the schematic organization of modular PKS as exemplified by tylosin (Tyl) PKS, which is 16-membered macrolide produced by Streptomyces fradiae. The tylosin PKS includes one loading module and seven extension modules terminating in thioesterase (TE) domain to generate tylactone.

Fig. 2. Biosynthetic gene assembly of tylosin biosynthesis gene cluster illustrating condensation and modification of different extender units to form tylactone aglycone which is further decorated with different post-modification enzymes to form tylosin.
and methyltransferases (MTs) [26]. By post-PKS tailoring enzymes such as cytochrome P450, the product is released, the biosynthesis is further extended by post-PKS tailoring enzymes such as cysteine P450 monoxygenase (CYP450), glycosyltransferases (GTs) and methyltransferases (MTs) [26].

Despite the numerous reports on the “canonical” organization and co-linearity in most of the type I PKSs, non-canonical examples of type I PKS are popular [27]. The skipping over of the extraneous functional domains or modules leading to the formation of unusual intermediates or final compounds have been reported [28, 29]. Similarly trans-acting domains have been uncovered from various polyketide biosynthesis. These trans-enzymes are usually physically separate from the usual modifying domains in the modular PKSs, but they act at specific points during the processing of the nascent acyl chains. One of the prominent examples is trans-AT or AT-less biosynthesis of polyketides whereas AT activity is provided at each elongation step in trans by free-standing AT usually encoded in the biosynthetic gene clusters [30]. Trans-ER has been characterized from lovastatin polyketide biosynthesis [31] and switchable ER domain has been reported in azalomycin F biosynthesis [32]. Similarly, some trans-acting thioesterases (TE type II) are responsible for editing function by hydrolytic removal of aberrant residues blocking the megasynthase, participation in substrate selection, intermediate, and product release [33]. Similarly broadly selective acyltransferase has been characterized from the polyketide synthase of splenocin [34].

The detailed information on extended unit promiscuity and orthogonal protein interaction of ACP and trans-AT has been also availed [35, 36]. So, these type of new information are not only providing novel insight on the biosynthetic mechanism of polyketides but also providing opportunities for plausible bio-engineering of these macrolides. Basically, the diversification of macrolides can be tuned at four major steps throughout biosynthesis through (1) choice of the building block and chain length, (2) reduction and stereochemical arrangement of β-keto intermediates, (3) rearrangements and secondary cyclizations, and (4) post-PKS tailoring [37]. Recent information on the protein structure of the enzymes and advanced genetic manipulation techniques provides enormous opportunity for fine tuning the post-PKS steps to generate novel or structurally diversified macrolides [38, 39].

Figure 3 depicts the plausible modification centers in macrolide that can be altered by utilizing different engineering aspects in the actinobacteria either by rational modification on PKS or post-PKS steps.

**Precursor-directed biogenesis of novel antibiotics**

The prolific generation of mutant bugs to the many pre-existing drugs has caused pitfall in efficiency of enhancement approach as a panacea for addressing the issues of drug resistance. Nevertheless, precursor directed biogenesis can still substantiate as a promising technique by providing a fertile platform for structurally diversifying the antibiotics, whereas the altered natural product precursors are subjected to the microorganisms and subsequently incorporated to reconstitute the product of interest [40]. The alternative precursor-directed biosynthesis can be utilized as an approach where the chemical and biological inputs are assembled for generation of novel natural products. For example, an orally active β-lactam antibiotic, penicillin V (phenoxymethylpenicillin), was produced by adding phenoxyacetic acid to fermentations of *Penicillium chrysogenum* [41].

But the major drawbacks of this approach can be inherent competition between alternative precursors and natural precursors, rendering the yield of novel derivatives to be low. However, this shortcoming can be overruled by blocking the synthesis of natural precursors, either by mutating key genes in the respective bio-synthetic pathway or by adding specific inhibitors of biosynthetic enzymes [42]. This approach in which the biosynthetic pathway is coupled with the feeding of synthetic starter precursors, where the precursors are reorganized in the biosynthetic pathway to remodel the final compound can be otherwise be termed "chemosynthetic biogenesis". Hence utilizing the benefits of this approach, various novel analogs of erythromycin and other polyketides are generated [43–47].

Fundamentally for generating diversities of analogs of erythromycin, a designed mutant of a modular PKS by inactivation were generated, that lacked early-stage enzyme activities. DEBS (KS19), a mutant of DEBS that was inactivated by site-directed mutagenesis of the β-ketoacyl-ACP synthase domain of module 1 (KS1) was used for precursor mediated structural diversification strategy [42]. The native KS1 domain catalyzes the first condensation step of 6-deoxyerythronolide B (6-deB) biosynthesis (Fig. 4a) but the DEBS (KS19) mutant is incapable of carrying out the first round of polyketide chain elongation from the propionyl-CoA and methyldonor-CoA causing incapability for the formation of the macrolide 6-deB. In turn, by the introduction of synthetic diketide and triketide such as the N-acetyl cysteamine (SNAC) thioester, which are analogs of the
natural diketide intermediate to *Streptomyces coelicolor* CH999/pJRJ2, an engineered strain harboring DEBS (KS18), various novel analogs of erythromycin were generated (Fig. 4b) [48].

**Mutasynthesis**

The precursor directed biogenesis has been utilized and still remains as a promising strategy for structurally diversifying and generating versatile chemical identities with superior properties or activities. But, the major drawback clinging to these approaches, most important being that mixture of natural and nonnatural products with similar physical properties are often produced, leading to complex downstream purification procedures; high concentrations of synthetic precursor are often required to compete with the preferred natural precursor and; a limited range of intermediates are efficiently incorporated into the final product. So, the precursor-directed biosynthesis has been complemented with mutasynthesis approach whereas the naturally occurring precursor pathways are inactivated by mutation to remove the competition with natural precursors.

*Streptomyces avermitilis* mutant (*S. avermitilis Δbkd*) was generated wherein the enzymes, branched chain fatty acid dehydrogenase complex Bkd required for generating the precursors 2-methylbutyryl-CoA and isobutyryl-CoA were inactivated. Different precursor analogs were fed to the mutant and a cyclohexyl-containing avermectin derivative (later named doramectin) was generated with increased antiparasitic activity [49]. Similarly, the deletion of 5-chlorodeoxyadenosine (a precursor for chloroethylmalonyl-CoA) biosynthetic genes in *Salinispora tropica* [50] and exogenous supplementation of 5-fluorodeoxyadenosine resulted in the generation of fluorosalinosporamide.

**Combinatorial biosynthesis for diversification of antibiotics**

“Combinatorial biosynthesis” is one of the promising strategies for the genesis of novel analogs of predominant antibiotics or modifying their structural aspects for better pharmacological properties. This approach intervenes with the strategies for the genetic engineering of natural product biosynthesis to obtain new molecules, including the use of genetics in medicinal chemistry [51]. It has been an important approach to generate chemical diversity by precise genetic manipulations and thus implies with the possibility of generation of large libraries of complex compounds to feed a modern high-throughput screening operation [51, 52]. Thus, combinatorial
Fig. 4  a Biosynthesis pathway assembly of erythromycin. b Biosynthesis of diverse erythromycin derivatives using *Streptomyces coelicolor* deficient in KS1<sup>13</sup>. Different activated synthetic diketides and triketides were supplemented to the culture.
biosynthesis is a recent addition to the metabolic engineering toolbox by which genes responsible for individual metabolic reactions from different organisms are combined to generate the metabolic pathways to biosynthesize the desired products [53]. Fundamentally, it can be distinguished from mutasynthesis approach on the bases that a mutasynthesis is an approach where there is inactivation of some key functional genes, thus perturbing the biosynthesis pathway to new products by supplementation of feasible precursors or chemical entities; whereas combinatorial biosynthesis rely on additional gene functions by heterologous expression of functionally similar or diverse genes so that the pathway is tuned for crafting novel analogs. It has been widely applied to achieve new derivatives related to polyketides, coumarins, indolocarbazoles and other types of antibiotics [53–55].

Among the compounds that have been developed into medicines, including the antimicrobials and antibiotics, the polyketides occupy significant part. The polyketides are produced as a diverse array of products manifested by the bacterial megaenzyme polyketide synthases (PKSs). The distinct modularity in the genetic architecture of these PKSs provides sufficient ground for expecting feasibility for engineering the enzymes to produce novel drug candidates, by ‘combinatorial biosynthesis’ [56].

The supplementation of the shikimate-derived cyclohexyl-CoA biosynthetic pathway into S. avermitilis Δbkd enabled the production of doramectin without cyclohexanoic acid supplementation [57]. Similarly, supplementation of diverse carboxyl acid starter unit to spinosyn PKS containing loading modules of avermectin or erythromycin could generate diverse spinosyn analogs [58]. Similarly, multiple bioactive macrolides were generated by hybrid modular PKS from pikromycin gene cluster, erythromycin gene cluster, and tylosin gene cluster, whereas rigorous interchange of modules is employed between the PKSs [59]. This work demonstrated the unique capacity of combinatorial biosynthesis for accelerating the creation of novel biologically active natural products.

By utilizing S. venezuelae based combinatorial biosynthesis machinery, many novel analogs of various secondary metabolites with diverse structure and diverse activities have been generated [60–64]. S. venezuelae ATCC 15439 was engineered for deletion of genes responsible for biosynthesis and attachment of TDP-4-keto-6-deoxy-d-glucose and the strain was designated as S. venezuelae YJ003. The sugar gene cassettes encoding for deoxy sugars biosynthesis and glycosylation were expressed in the engineered strain to generate olivosyl and quinovosyl derivative of various macrolides [60]. S. venezuelae was genetically engineered for deletion of the entire biosynthetic gene cluster encoding the pikromycin PKS and desosamine biosynthetic enzyme [61]. After crafting the amenable host for combinatorial biosynthesis, it was used multifarious for generation of different analogs of targeted polyketides. The engineered deoxy sugar biosynthetic pathways for biosynthesis of thymidine diphosphate (TDP)-d-quinovose or TDP-d-olivose along with substrate flexible glycosyltransferase–auxiliary protein pair DesVII/DesVIII from S. venezuelae were expressed in the mutant strain to which 12-, 14-, and 16-membered ring macro lactones i.e. 10-deoxymethynolide, narbonolide, and tylactone, respectively were feed to generate corresponding quinovose- and olivose-glycosylated macrolides. The conversion of 12-, 14-, and 16-membered ring macro lactones including 10-deoxymethynolide, narbonolide, and tylactone were achieved in engineered S. venezuelae strain with deoxy sugar biosynthetic pathways (TDP-d-quinovose or TDP-d-olivose) together with glycosyltransferase-auxiliary protein (DesVII/DesVIII) and produce their glycosylated scaffolds as quinovosyl and olivosyl macro lactones. The synthesized compounds were YC-17 and narbomycin. Similarly, while replacing the DesVII/DesVIII by substrate-flexible glycosyltransferase TylMII coupled with partner protein TylMIII derived from S. fradiae, a mycaminosyl derivative of tylactone (5-O-mycaminosyl tylactone) was produced [61]. Similarly, expression of complete biosynthetic pathways for the biosynthesis of TDP-3-de methyl-d-chalosyl or TDP-1-rhamnosyl together with the glycosyltransferase-auxiliary protein pair DesVII/DesVIII along with subsequent feeding of 16-membered ring macrolactone tylactone was fed to this engineered host, which in turn successfully produced 3-O-demethyl-d-chalcosyl, 1-rhamnosyl, and d-quinovosyl derivatives [62]. Similarly, using S. venezuelae YJ003 and expression of complete biosynthetic pathways for the biosynthesis of TDP-3-dimethyl-d-chalosyl or TDP-1-rhamnosyl together with DesVII/DesVIII, novel narbomycin derivative decorated with 1-rhamnosyl or 3-O-demethyl-d-chalcosyl were generated. These novel analogs exhibited greater antibacterial activity than narbomycin and the clinically relevant erythromycin [62]. In another instance, for another aglycone YC-17, the native d-desosamine was replaced by d-quinovose, l-olivose, l-rhamnosyl, and d-boivinose to generate YC-17 glycoside analogs as d-quinovosyl-10-deoxymethylolide, l-olivosyl-10-deoxymethylolide, l-rhamnosyl-10-deoxymethylolide, and d-boivinosyl-10-deoxymethylolide respectively by expression of gene cassette responsible for biosynthesis of respective deoxy sugars (Fig. 5). The assessment of biological activity indicated that 1-rhamnosyl-10-deoxymethylolide exhibited better activities against clinically isolated erythromycin-resistant pathogenic strains, as well as erythromycin-susceptible strains relative to...
Fig. 5 Structures of different sugars conjugated macrolides produced using TDP-sugars biosynthesis pathway engineered *Streptomyces* recombinant strains.
Metabolic engineering approaches in actinomycetes for macrolide biosynthesis

The major constraint for biosynthesis of macrolides in the producer-host has been abundant availability of precursors and cofactors, the lower expression level of biosynthetic genes and regulation of the biosynthetic gene/gene clusters. Generally, the bottlenecks in biosynthetic pathways restrict the substantial production of the natural product in desired titers. This is significantly associated with the limitations of the flux of key precursors from primary metabolism to secondary metabolic pathways [68, 69]. Generally, the precursors/cofactors are derived from primary metabolism including glycolysis, pentose phosphate pathway, tricarboxylic acid cycle and amino acid/nucleic acid metabolism [70]. Thus these types of limitations can be overcome by amplifying the gene or genes that encode enzymes associated with such bottlenecks resulting in increased enzyme levels to diminish the bottleneck effects and hence, improved titers can be achieved [71, 72]. Fundamentally, regulation and correlation of precursor supply for improving natural product amounts are focused on carbohydrate metabolism, fatty acid precursors, and intracellular cofactor supplies [73, 74]. There are ample examples illustrating the genetic circuit guided pathway engineering approaches for enhancing the secondary metabolites of importance [75], such as heterologous overexpression of the S-adenosyl-L-methionine (SAM) synthetase metK, improved production of different antibiotics, such as actinorhodin, avermectin, and pikromycin [76, 77]. For example, the engineering of methylmalonyl-CoA biogenesis pathway by generating MCM gene, methylmalonyl-CoA mutase (mutB) knock out mutant of S. erythraea, there was an enhanced level of erythromycin in the carbohydrate-based medium. However, there was an elevated level of erythromycin in S. erythraea recombinant containing MCM operon (meaA, mutB, meab, mutR) in the oil-based medium [78]. Similarly by supplementation of cheap primary sources which subsequently contribute for specific fatty acid precursors viz. acetyl-CoA, malonyl-CoA, methyl malonyl-CoA and ethyl malonyl-CoA along with precursor redirecting enzyme complexes such as acetyl CoA carboxylase, and propionyl CoA carboxylase different antibiotics such as nargenicin A1, pikromycin, and erythromycin were elevated to significant level [79–82]. Hence, metabolic engineering combined with redirection of specific precursors can be a rational approach for enhancing the secondary metabolites of importance. Similarly, such approaches for enriching the acyl-CoA precursors have been used for an elevated level of diverse macroalides (Table 1). Recently, various engineering strategies for directing the catabolism of branched-chain amino acids (BCAA) into various acyl-CoA compounds has extended the opportunities for metabolic engineering of acyl-CoA pathways and yield improvement of macrolides [83].

Similarly, the expression of regulatory genes has been promising strategies to enhance the production titer or activation of novel macrolides in diverse actinomycetes. Generally, the introduction of synthetic or natural promoter has been effective for triggering either overproduction or activation of silent/cryptic gene clusters with low or no expression [84–89]. The metabolic engineering approaches utilizing overexpression/deletion of various global regulators or pathway-specific positive regulators are utilized for either enhancing the production yield or obtaining novel macrolides from native hosts/heterologous hosts (Table 1).

The availability of the crystal structure of complete module of PKS [16, 90] or its constituent domains as ACP [91], dehydratase [92], thioesterase [93, 94] has provided a better understanding on the mechanism of macrolactone biosynthesis. In case of polyketide biosynthesis, the
Fig. 6 Generation of different macrolactones using selected enzymes such as PikC, EryF and OleP.
AT domain is crucial for controlling the recognition of the extender unit. Thus, there is a possibility of changing the building block specificity and the basic backbone of the polyketide by altering the AT domain. Such valuable information has been utilized for rational engineering of macrolactones. The site-directed mutagenesis of the domains or intact domain exchange to change their substrate specificities has been widely used for generating diverse analogs of the macrolides, which have been reviewed elsewhere [13]. The exchange of AT domain by domain swapping can cause impaired protein folding [95]. However, Yuzawa et al. identified the highly conserved boundaries and exhibited the feasibility of AT domain replacement in macrolides [96]. But the direct engineering of innate AT domain can be a more reliable alternative for varying the substrate ranges [97]. For example, the site-directed mutagenesis of AT domain and feeding of 2-propagylmalonyl-SNAC to S. erythraea (containing AT6 of DEBS mutated with Val295 to Ala) to generate 2-propargyl erythromycin [98]. The mutation is not only capable of extending the substrate specificity to natural extender units but also alter the specificity non-natural extender units. For example, the selected mutation at Tyr189 in DEBS3 AT6 domain resulted in the dramatic changes in product distribution by accepting diverse non-natural extender units [99].

Similarly, novel derivatives of NPP have been generated by site-directed mutagenesis in enoyl reductase domain in module 5 of the NPP A1 polyketide synthase NppC. The compound exhibited comparable antifungal activity against Candida albicans with lesser toxicity than antifungal, amphotericin B [100]. However, such kind of domain modification may create inactive proteins or change the chemistry of inter-domain interactions. So entire domain exchange has been a superior option and several analogs of erythromycin have been generated by replacing methylmalonyl-specific acyltransferase (AT) domains of the 6-deoxyerythronolide B synthase (DEBS) with malonyl-, ethylmalonyl-, or methoxymalonyl-specific domains [101].

Similarly, metabolic engineering approach has been performed for complete exchange of the module. For example, the loading module from the rifamycin biosynthetic pathway as a substitution for the original loading domain was incorporated in the PKS so that the altered PKS was amenable for accepting benzoate as starter unit.

Table 1  Metabolic engineering approaches used for enhancing the production of diverse macrolides

| Compound        | Strain                          | Approach                                                                 | References |
|-----------------|---------------------------------|--------------------------------------------------------------------------|------------|
| Native host     |                                 |                                                                          |            |
| Epothilone      | Sorangium cellulosum            | Expression of propionyl-CoA synthetase, which converts propionate into   | [148]      |
|                 |                                 | propropionyl-CoA, the precursor of methylmalonyl-CoA                      |            |
| Nargenicin A1   | Nocardia sp. CS682              | Over-expression of ACCase complex for enhancement of production          | [82]       |
| Natamycin       | S. chattanoogensis L10          | Overexpression of the endogenous PPTase SchPPT for enhancement of        | [149]      |
| Tylosin         | S. fradiae                      | Different approaches for enhancement of production titer: SARP regulators | [150–152]  |
|                 |                                 | tylS and tyLP are overexpressed                                          |            |
|                 |                                 | Inactivation of a transcriptional repressor (tylQ)                       |            |
|                 |                                 | Disruption of tyLP encoding a γ-butyrolactone receptor                   |            |
| Spiramycin      | S. ambofaciens                  | Overexpression of pathway-specific regulator srm22 or srm40 increased   | [153]      |
|                 |                                 | spiramycin production                                                    |            |
| Millibemycin    | S. bingchengensis               | Enhancement by overexpression of pathway-specific regulator milR         | [154]      |
| Pikromycin       | S. venezuelae                   | Enhancement of production by overexpressing genes of branched chain     | [83]       |
|                 |                                 | amino acids catabolism                                                  |            |
| Stambomycins    | S. ambofaciens                  | Overexpression of pathway-specific regulator samR0484 triggers production| [155]      |
| Heterologous hosts |                                 |                                                                         |            |
| FK 506          | S. clavuligerus CKD1119         | Expression of mutB from S. erythraea                                   | [156]      |
| Methoxymalonate-plate-nolid analog | S. fradiae                  | Introducing the biosynthetic pathway for methoxycarbonyl-ACP             | [112]      |
| Midecamycin     | S. fradiae                      | Enhancement of production by introducing the biosynthetic pathway for    | [112]      |
|                 |                                 | methoxymalonyl-ACP from the FKS20 producer S. hygroscopicus             |            |
| Pikromycin       | S. venezuelae                   | Enhancement of production by expression of two global regulators, metK1-sp| [157]      |
|                 |                                 | and afsR-sp, from Streptomyces peucetius                               |            |
| Tylosin         | S. venezuelae                   | Overexpression of pikD, a pathway-specific regulator from pikromycin     | [158]      |
|                 |                                 | biosynthetic pathway                                                   |            |
instead of the propionyl-CoA used in native. By this strategy, a novel benzyl-erythromycin analog was generated and by utilizing further precursor flux enhancement and pathway engineering approaches the titer of the novel derivative was substantially increased (Fig. 7). The novel derivative was capable to show comparable activity to the parent compound whereas showing pronounced efficacy against the erythromycin resistant pathogens [102]. Similarly, the domain swapping of pikromycin thioesterase to linear polyketide tautomycetin (TMC) was able to generate the cyclized form of macrolactones [103].

In general, most of the actinomycetes strain is capable of generating profuse secondary metabolites with different structures or activities. Most often these chemical entities share common scaffold and thus similar precursor régimes. Thus, the precise and efficient manipulation of modular PKSs is often hindered by biological constraints posed by organisms (principally actinomycetes) due to their intricate biological pathways and complex distribution of precursor flux for the constitution of different secondary metabolites. To address this constraint, an heterologous expression host as Escherichia coli was engineered with the introduction of the three DEBS genes from S. erythraea, the sfp phosphopantetheinyl transferase gene from Bacillus subtilis, and the genes encoding a heterodimeric propionyl-CoA carboxylase from S. coelicolor [104]. This engineered E. coli BAP1 strain was utilized for fortifying generation of novel analogs of erythromycin (Fig. 7), as described previously. Further, the production was fine-tuned by reducing the total number of plasmids [105] and utilizing the BAC vector [106]. The metabolic engineering approach by eliminating competitive native pathway for nucleotide-activated sugar biosynthesis pathways (vioA/
The metabolic engineering approach was employed for expanding the formation of novel erythromycin analogs by altering the tailoring enzymes involved in sugar biosynthesis. Among them few of the novel analogs exhibited promising activity against the erythromycin-resistant strain of *B. subtilis*, which provided a rationale of this diversification strategy for increasing the therapeutic potential of erythromycin [107].

Thus heterologous expression has been an efficient approach of metabolic engineering where a single gene, or a set of genes, or entire biosynthetic pathway genes are introduced in the microbial host to identify and engineer the corresponding natural products [108]. When if the native producer strains are not genetically tractable or not amenable to metabolic engineering approaches, the heterologous hosts provide an efficient approach for gaining access to secondary metabolites encoded by the particular BGCs. In addition, the generation of metabolic engineering by removing the competing biosynthetic pathways to generate clean hosts provides a suitable platform for isolation, characterization, and production of various macrolides [109, 110]. The generation of cluster free clean hosts provides new avenues for redirecting the flow of precursor pathways directly to the target secondary metabolite heterologously expressed [111]. Diverse macrolide biosynthesized through heterologous hosts are presented in Table 2. In some cases, the heterologous expression of the BGCs needs to be tuned by expression of the regulatory genes. For example, the heterologous expression of a tylosin gene cluster in *S. venezuelae* was enhanced by expression of *pikD*, a positive regulator from pikromycin biosynthetic pathway of *S. venezuelae*. In other cases, the tuning of heterologous expression by an engineered precursor pathway can enhance the production titer or generate novel derivatives in heterologous expression systems [112]. The introduction of the biosynthetic pathway for methoxymalonyl-ACP into an *S. fradiae* strain heterologously expressing the midecamycin pathway led to enhancement of midecamycin and generation of a novel compound as an analog of methoxymalonate-platenolide [112].

Recently, the biocatalytic/chemo-biocatalytic approach employing a heterologous expression of the partial PKS and substantial modification has been employed as an effective approach for generating novel macrolides [113]. For example, the Pik pentaketide precursor was supplemented to the expressed protein of PikAIII-TE or PIKAIII-PikAV to generate the macrolactones, 10-deoxy-methynolide, and narbonolide. Further biotransformation with engineered *S. venezuelae* could generate diverse derivatives related to pikromycin and methymycin. Similarly, activated synthetic hexaketide was further extended with a methyl malonyl and malonyl units followed by lactonization to form tylectone aglycon by in vitro catalysis using tylosin biosynthesis complementary modules (module 6 and 7 encoded by *JuvEIV* and *JuvEV* genes).

### Table 2. Diverse macrolide biosynthesized through heterologous hosts

| Compound    | Producer-host          | Heterologous host                                                                 | References          |
|-------------|------------------------|---------------------------------------------------------------------------------|---------------------|
| Avermectin  | *S. avermitilis*       | *S. lividans*                                                                   | [159]               |
| Chalcomycin | *S. bikiniensis*       |                                                                                 |                     |
| Epothilone  | *Sorangium cellulorum* | *S. coelicolor*, *M. xanthus*, *E. coli*, *S. venezuelae*, *Mycococcus*         | [117, 161–166]      |
| Erythromycin| *Saccharopolyspora*    | *S. coelicolor*, *E. coli*                                                      | [167, 168]          |
| Megalomyces | *Micromonospora*       | *Saccharopolyspora*, *S. lividans*                                              | [169]               |
| Spinosyn    | *Saccharopolyspora*    | *S. albus*                                                                      | [118]               |
| Tylosin     | *S. fradiae*           | *S. venezuelae*                                                                 | [170]               |
| Midecamycin | *S. hygroscopicus*     | *S. fradiae*                                                                    | [112]               |
| Pikromycin  | *S. venezuelae*        | *S. coelicolor*, *S. lividans*                                                  | [171, 172]          |
| Oleandomycin| *S. antibioticus*      | *S. coelicolor*                                                                  | [171]               |
| Versipelostatin | *S. versipellis* 4083 | *S. albus*                                                                      | [173]               |
| Galbomolide B| *Streptomyces sp.* L335 | *S. coelicolor*                                                                  | [174]               |
| FKS06       | *S. tsukubaensis*      | *S. coelicolor*                                                                  | [175]               |
| Streptoseomycin | *S. seoulensis*         | *S. chartreusis*                                                                | [176]               |
| Nemadectin  | *S. cyanogenფieus*     | *S. avermitilis*                                                                | [110]               |
| Bafilomycin B1 | *Kitasatospora* setae KM-6054 | *S. avermitilis*                                                                | [110]               |
| Quinolidominic | *Micromonospora* sp. Y16 | *S. lividans*                                                                   | [173]               |
from juvenimicin BGC. The tyllactone was further bio-transformed to M-4365 G₁ using *S. fradiae* DHS 316 which is deficient of tyllactone BGC. This intermediate was modified into ten different macrolide derivatives using CYP450 and chemical oxidation methods [114, 115] (Fig. 8). This approach advanced the use of type I PKS enzymes in vitro for generation of novel antibiotics.

However, this method suffers from the limitations of scalability whereas the starting materials need to be supplied in sufficient amounts for sustainable production. In addition, there is a requirement of strict control in unwanted reactive centers but enough reaction in desired reaction centers, which makes these synthesis processes tedious and expensive. Thus, biological engineering of macrolides by using sustainable metabolism in the
The availability of detailed knowledge of diverse –omics related information can be successfully employed for fine tuning the heterologous expression of such macrolide compounds [118].

**Microbial biotransformation for modification of antibiotics**

Besides the precise genetic engineering approaches, microbial biotransformation strategies have attracted considerable interest for the post-modification of secondary metabolites in terms of their structural and functional characteristics [119–121]. Any changes in parental compounds in a later stage can refer to as post-modification in terms of structure and biotransformation is one of the well-studied and precise approaches to achieve such modifications with an optimal regio- and enantiobselection [122, 123]. However, the major modification includes cofactor-dependent hydroxylation/oxidation, dehydrogenation, methylation, glycosylation (O/C/N-glycosylation, deglycosylation), epoxidation, cyclization etc. [124–127], whereas the intracellular cofactors/enzymes present in the biotransformation host is responsible for desired modification of the supplemented substrate. Such whole-cell biotransformation can be achieved using various microbial species (*Streptomyces*, *Myxobacterium*, *Bacillus*, *Corynebacterium*, *Pseudomonas*, etc.) as a host.

A series of erythromycin D analogs conjugated with different sugar scaffolds were produced feeding 6-deoxyerythronolide B or 3-α-mycarosyl-erythronolide B in *E. coli* overexpressing the specific TDP-L-mycarose and TDP-desosamine sugar biosynthetic pathway [128]. Same biotransformation set-up was used for modification of erythromycin C, 3-α-mycarosyl-erythronolide B, azithromycin, and erythromycin D to modify them into megosamine conjugated products using reconstitutive TDP-L-megosamine biosynthetic pathway in *E. coli* [129, 130] (Fig. 9a). This experiment also suggested the possible routes for the production of diverse therapeutically important (antiparasitic, antiviral and antibacterial) compound megalomicin A including 12-deoxynucleoside triphosphate megalomicin A [130]. Importantly, sugar appendages present in macrolide antibiotics governs their biological properties and changes in them have a substantial effect [131]. So, deoxy sugar biosynthetic pathways are usually focused in terms of antibiotic modifications. 6-O-megosaminyl-erythromycin A, 6-O-megosaminyl-azithromycin, 6-O-epidigitoxosyl-erythromycin A and 6-O-daunosaminyl-erythromycin A were produced through the whole cell biotransformation. Their evaluation against several clinical isolates; standard and drug-resistant strains of human malarial parasites (*Plasmodium falciparum*) and liver stages of the rodent malaria parasite (*Plasmodium berghei*) were found more effective than parental compound [130].

Rosamicin, macrolide antibiotics isolated from the culture of soil bacterium was bio-transformed into 10, 11-dihydrorosamicin using *S. venezuelae* which showed enhanced in vitro antibacterial activity against MRSA [132]. Likewise, natural oligomycin A and semi-synthetic tilmicosin are considered and bio-hydrogenated using *S. venezuelae* and structurally modify into 2, 3-dihydro-oligomycin A and 10, 11-dihydro-tilmicosin (Fig. 9b). This changes in natural scaffold oligomycin and tilmicosin brought increased activity against *S. cerevisiae* and *Bacillus subtilis* respectively [133]. Similarly, macrocyclic lactone antibiotic streptogramin A namely 5, 6-dihydrovirginiamycin M1 was created by feeding virginiamycin M1 into a culture of recombinant *S. venezuelae* through the mechanism of bio-dehydrogenation catalysis [134]. The generated analog showed enhanced anti-MRSA activity compared to the parent compound.

**Conclusions and future perspectives**

Actinobacteria have been already established as the promising platform for the production of macrolides and their novel derivatives. Moreover, the recent advances in various “omics” provides new paths for uncovering the genomic information and their expression levels. Moreover, the availability of various bioinformatics tools for classifying the genome to BGCs and analysis of the products by versatile metabolome analyzing tools helps in connecting the genome to a particular molecule, which is also otherwise called as "genome mining" approach [135–139]. In addition, the current success of enzyme/host engineering has narrowed down the gap between the understanding of PKS biosynthetic logic and its propensity for PKS diversification. The advances in genome sequencing, protein crystallography, and gene-synthesis system have made it feasible for designing, building and testing chimeric PKSs. The advancement in the analytical methods by mass spectrometry and molecular networking have increased our capacity for detecting the products [140]. The feasibility of the optimization of production hosts either native or heterologous by computational and systems biological tools [141] provides an effective or alternative route for fluxing the precursors toward the
biosynthesis from such chimeric PKS. Various genome engineering techniques such as Multiplex Automated Genome Engineering (MAGE) [142, 143] and Clustered Regularly Interspaced Short Palindromic Repeats (CRISPRs)/CRISPR associated enzyme (Cas) [144, 145] provides ample of opportunities for precise metabolic engineering of the PKS and post-PKS biosynthetic steps in the native/heterologous hosts. Additionally, diverse BGCs cloning techniques as Bacterial artificial chromosome (BAC) cloning, Gibson assembly, Linear–linear homologous recombination (LLHR), Golden Gate assembly and Transformation-associated recombination (TAR) have played pivotal role in unlocking diverse NP resources [146, 147]. The availability of detailed genomic information of producer strains and precise analysis facilitated by efficient cloning methods and utilizing the metabolically engineered host system can be next generation approach for isolation of novel macrolides or enhanced production of existing macrolides with pharmaceutical values.

Fig. 9  a Biosynthesis of glycosylated macrolides from different TDP-sugars (TDP-L-mycarose, TDP-desosamine, TDP-megosamine) biosynthesis pathway overexpressed recombinant E. coli strains supplemented with corresponding macrolactone/macrolides. b Biotransformation of macrolides using Streptomyces venezuelae strain.
Fig. 9 continued

- Rosamicin
- 10, 11-Dihydrorosamicin
- Oligomycin A
- 2,3-Dihydro-oligomycin A
- Virginiamycin M1
- 5, 6-Dihydrovirginiamycin M1
- Tilmicosin
- 10, 11-Dihydro-tilmicosin

*S. venezuelae*
Abbreviations

BGCs: biosynthetic gene clusters; PKSs: polyketide synthases; NRPS: nonribosomal peptide synthase; DEBS: 6-deoxyerythronolide B synthase; NPP: nystatin-like Pseudomonas polype; MRSA: methicillin resistance Staphylococcus aureus; NAICE: Multiplex Automated Genome Engineering, CRISPRs: Clustered Regularly Interspaced Short Palindromic Repeats.

Authors’ contributions

DD and RPP wrote the manuscript. JKS gave valuable suggestions. All authors read and approved the final manuscript.

Funding

This research was supported by grant from National Research Foundation of Korea to RPP (NRF-2017R1C1B5018056), JKS (NRF-2017R1A2A05000939) and DD (NRF-2017R1D1A1B03036273).

Availability of data and materials

Not applicable.

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Author details

1Department of Life Science and Biochemical Engineering, Sun Moon University, 70 Sunmoon-ro 221, Tangjeong-myeon, Asan-si 31460, Chungnam, Republic of Korea. 2Department of Pharmaceutical Engineering and Biotechnology, Sun Moon University, 70 Sunmoon-ro 221, Tangjeong-myeon, Asan-si 31460, Chungnam, Republic of Korea.

Received: 14 January 2019 Accepted: 2 August 2019 Published online: 13 August 2019

References

1. Newman DJ, Cragg GM. Natural products as sources of new drugs from 1981 to 2014. J Nat Prod. 2016;79:629–61.
2. Dhakal D, Sohng JK. Coalition of biology and chemistry for ameliorating antimicrobial drug discovery. Front Microbiol. 2017;8:734.
3. Olano C, Méndez C, Salas J. Antitumor compounds from marine actinomycetes. Mar Drugs. 2009;7:210–48.
4. Genilloud O. Actinomycetes: still a source of novel antibiotics. Nat Prod Rep. 2017;34:1203–32.
5. Dhakal D, Pokhrel AR, Shrestha B, Sohng JK. Marine rare Actinobacteria: isolation, characterization, and strategies for harnessing bioactive compounds. Front Microbiol. 2017;8:1106.
6. Barka EA, Vatsa P, Sanchez L, Meier-Kolthoff JP, Klenk HP, Clément C, Ouhdouch Y, van Wezel GP. Taxonomy, physiology, and natural products of actinobacteria. Microbiol Mol Biol Rev. 2015;80:1–43.
7. Kist HA. Introduction to the macrolide antibiotics. In: Schonfeld W, Kirst HA, editors. Macrolide antibiotics. Basel: Birkhauser Verlag. 2002. p. 1–13.
8. Gaynor M, Mankin AS. Macrolide antibiotics: binding site, mechanism of action, resistance. Curr Top Med Chem. 2003;3:949.
9. Park SB, Han AR, Ban YH, Yoo YJ, Kim EJ, Yoon YJ. Genetic engineering of macrolide biosynthesis: past advances, current state, and future prospects. Appl Microbiol Biotechnol. 2010;85:1227–39.
10. Arsic B, Barber J, Čikoš A, Mladenovic M, Stankovic N, Novak P. 16-membered macrolide antibiotics: a review. Int J Antimicrob Agents. 2018;51:283–98.
11. Demain AL, Sanchez S. Microbial drug discovery: 80 years of progress. J Antibiot. 2009;62:5–16.
12. Armutzias GD, Chalotic A, Mossiols D. Discovery strategies of bioactive compounds synthesized by nonribosomal peptide synthetases and type-I polyketide synthases derived from marine microorganisms. Mar Drugs. 2016;14:E80.
13. Weissman KJ. Genetic engineering of modular PKGs: from combinatorial biosynthesis to synthetic biology. Nat Prod Rep. 2016;33:203–30.
14. Dhakal D, Sohng JK. Commentaries: toward a new focus in antibiotic and drug discovery from the Streptomyces arsenal. Front Microbiol. 2015;6:727.
15. Wohlleben W, Mast Y, Muth G, Rötgem M, Stegemann E, Weber T. Synthetic biology of secondary metabolite biosynthesis in actinomycetes: engineering precursor supply as a way to optimize antibiotic productivity. FEBS Lett. 2012;586:2171–6.
16. Dutta S, Whicher JR, Hansen DA, Hale WA, Chemler JA, Congdon GR, Narayan AR, Håkansson K, Sherman DH, Smith JL, Skiniotis G. Structure of a modular polyketide synthase. Nature. 2014;510:512.
17. Whicher JR, Dutta S, Hansen DA, Hale WA, Chemler JA, Dosey AM, Narayan AR, Håkansson K, Sherman DH, Smith JL, Skiniotis G. Structural rearrangements of a polyketide synthase module during its catalytic cycle. Nature. 2014;510:560–4.
18. Staunton J, Weissman KJ. Polyketide biosynthesis: a millennium review. Nat Prod Rep. 2001;18:380–416.
19. Chen AY, Schnarr NA, Kim CY, Cane DE, Khosia C. Extender unit and acyl carrier protein specificity of ketyosynthetic domains of the 6-deoxyerythronolide B synthase. J Am Chem Soc. 2006;128:3061–74.
20. Fischbach MA, Walsh CT. Assembly-line enzymology for polyketide and nonribosomal peptide antibiotics: logic, machinery, and mechanisms. Chem Rev. 2006;106:3468–96.
21. Keatinge-Clay AT. The structures of type I polyketide synthases. Nat Prod Rep. 2012;29:1050–73.
22. Xu W, Qiao K, Tang Y. Structural analysis of protein-protein interactions in type I polyketide synthases. Crit Rev Biochem Mol Biol. 2013;48:98–122.
23. Baltz RH, Sen ET. Properties of Streptomyces fradiae mutants blocked in biosynthesis of the macrolide antibiotic tylosin. Antimicrob Agents Chemother. 1981;20:214–25.
24. Cundliffe E, Bate N, Butler A, Fish S, Gandechoa A, Merson-Davies L. The tylosin-biosynthetic genes of Streptomyces fradiae. Antonie Van Leeuwenhoek. 2001;79:229–34.
25. Fiers WD, Dodge GJ, Li Y, Smith JL, Feckl RA, Aldrich CC. Tylosin polyketide synthase module 3: stereospecificity, stereoselectivity and steady-state kinetic analysis of β-processing domains via diffusible, synthetic substrates. Chem Sci. 2015;6:5027–33.
26. Baltz RH, Seno ET, Stonesifer J, Wild GM. Biosynthesis of the macrolide antibiotic tylosin. A preferred pathway from tyloactone to tylosin. J Antimicrob Chemother. 1983;63:131–41.
27. Chen H, Du L. Iterative polyketide biosynthesis by modular polyketide synthases in bacteria. Appl Microbiol Biotechnol. 2016;100:541–57.
28. Beck BJ, Yoon YJ, Reynolds KA, Sherman DH. The hidden steps of domain skipping: macrolactone ring size determination in the pikromycin modular polyketide synthase. Chem Biol. 2009;16:575–83.
29. El-Sayed AK, Hothersall J, Cooper SM, Stephens E, Simpson TJ, Thomas CM. Characterization of the murpoxin biosynthesis gene cluster from Pseudomonas fluorescens NCIMB 10586. Chem Biol. 2003;10:419–30.
30. Helfrich EJ, Piel J. Biosynthesis of polyketides by trans-AT polyketide synthases. Nat Prod Rep. 2016;33:231–316.
31. Armes BD, Nguyen C, Bruegger J, Smith P, Xu W, Ma S, Wong E, Wong S, Xie X, Li WH, Vederas JC. Crystal structure and biochemical studies of the trans-acting polyketide enoyl reductase LovC from lovastatin biosynthesis, Proc Natl Acad Sci USA. 2012;109:11449–50.
32. Xu W, Zhai G, Liu Y, Li Y, Shi Y, Hong K, Hong H, Leadlay PF, Deng Z, Sun Y. An iterative module in the azalomycin F polyketide synthase contains a switchable enoylreductase domain. Angew Chem Int Ed Engl. 2013;52:12640–4.
33. Musiol-Kroll EM, Wohlleben W. Acyltransferases as tools for polyketide synthase engineering. Antibiotics (Basel). 2018;7:E62.
36. Carpenter SM, Williams GJ. Extender unit promiscuity and orthogonal protein interactions of an aminomalonyl-ACP utilizing trans-acytrolase from zwittemycin biosynthesis. ACS Chem Biol. 2018. https://doi.org/10.1021/acschembio.8b00867

37. Cummings M, Breitling R, Takano E. Steps towards the synthetic biology of polyketide biosynthesis. FEMS Microbiol Lett. 2014;351:116–25.

38. Olano C, Méndez C, Salas JA. Post-PKS tailoring steps in natural product-producing actinomycetes from the perspective of combinatorial biosynthesis. Nat Prod Rep. 2010;27:571–616.

39. Nepal KK, Wang G. Streptomyces: surrogate hosts for the generic manipulation of biosynthetic gene clusters and production of natural products. Biotechnol Adv. 2018;37(1):1–20.

40. Wohlleben W, Pelzer S. New compounds by combining "modern" genetics and "old-fashioned" mutasynthesis. Chem Biol. 2002;9:1163–4.

41. Demain AL, Elander RP. The β-lactam antibiotics: past, present, and future. Antone Van Leeuwenhoek. 1999;75:5–19.

42. Kinoshita K, Pfeifer BA, Khosla C, Cane DE. Precursor-directed polyketide biosynthesis of erythromycin analogs by an engineered polyketide synthase. Science. 1997;277:367–9.

43. Jacobsen JR, Hutchinson CR, Cane DE, Khosla C. Precursor-directed biosynthesis of 12-ethyl erythromycin. Bioorg Med Chem. 1998;6:1171–71.

44. Weissman KJ, Bycroft M, Cutter AL, Hanefeld U, Frost EJ, Timoney MC, Leaf T, Cadapan L, Carreras C, Regentin R, Ou S, Woo E, Ashley G, Licari J, Menzella HG, Reeves CD. Combinatorial biosynthesis for drug development. J Nat Prod. 2006;69:2629–33.

45. Zhang W, Tang Y. Combinatorial biosynthesis of natural products. J Med Chem. 2008;51:2629–33.

46. Eustaquio AS, Moore BS. Mutasynthesis of fluorosalinosporamide, a new avermectin highly efficacious against gastrointestinal nematodes. J Antibiot (Tokyo). 1998;51:2629–33.

47. Heide L, Gust B, Anderle C, Li SM. Combinatorial biosynthesis, metabolic genomics and "old-fashioned" mutasynthesis. Chem Biol. 2002;9:1163–4.

48. Kinoshita K, Williard PG, Khosla C, Cane DE. Precursor-directed biosynthesis towards novel erythromycins through in vitro studies on a bimodular polyketide synthase. Chem Biol. 1998;5:743–54.

49. Luo Y, Li ZB, Liu D, Zhang L, Chen Y, Jia B, Zeng BX, Zhao H, Yuan YJ. Engineered biosynthesis of natural products in heterologous hosts. Chem Soc Rev. 2015;44:5256–90.

50. Zhang MM, Wang Y, Ang EL, Zhao H. Engineering microbial hosts for production of bacterial natural products. Nat Prod Rep. 2016;33:963–87.

51. Jung WS, Kim EJ, Yoon YJ. New olivosyl derivatives of methymycin/pikromycin from an engineered strain of Streptomyces venezuelae. FEMS Microbiol Lett. 2004;238:391–9.

52. Jung WS, Han AR, Hong JS, Park JW, Cho J, Lee SR, Ban HY, Yoo YJ, Kim EI, Kim E, Park SR, Kim BG, Dong DG, Yoon YJ. Engineered biosynthesis of glycosylated derivatives of tylosin in Streptomyces venezuelae. J Microbiol Biotechnol. 2011;21:613–6.

53. Han AR, Shinde PB, Park JW, Cho J, Lee SR, Ban HY, Yoo YJ, Kim EI, Kim E, Park SR, Kim BG, Dong DG, Yoon YJ. Engineered biosynthesis of glycosylated derivatives of nargenicin A1 and creation of a novel derivative using a synthetic biology platform. Appl Microbiol Biotechnol. 2012;93:1147–56.

54. Shinde PB, Han AR, Cho J, Lee SR, Ban HY, Yoo YJ, Kim EI, Kim E, Song MC, Park JW, Lee DG, Yoon YJ. Combinatorial biosynthesis and antibacterial evaluation of glycosylated derivatives of 12-membered macrolide antibiotic YC-17. J Biotechnol. 2013;168:142–8.

55. Katz L. Manipulation of modular polyketide synthases. Chem Rev. 1997;97:2557–76.
102. Jiang M, Pfeifer BA. Improved heterologous erythromycin A production through expression plasmid re-design. Biotechnol Prog. 2013;29:862–9.

103. Fang L, Guell M, Church GM, Pfeifer BA. Heterologous erythromycin production across strain and plasmid construction. Biotechnol Prog. 2018;34:271–6.

104. Pfeifer BA, Adriaan SJ, Gramajo H, Cane DE, Khosla C. Biosynthesis of complex polyketides in a metabolically engineered strain of E. coli. Science. 2001;291:1790–2.

105. Jiang M, Fang L, Pfeifer BA. Improved heterologous erythromycin A production through expression plasmid re-design. Biotechnol Prog. 2013;29:862–9.

106. Luo Y, Enghiad B, Zhao H. New tools for reconstruction and heterologous expression of natural product biosynthetic gene clusters. Nat Prod Rep. 2016;33:174–82.

107. Zhang G, Li Y, Fang L, Pfeifer BA. Tailoring pathway modularity in the biosynthesis of erythromycin analogs heterologously engineered in E. coli. Sci Adv. 2015;1:e1500077.

108. Luo Y, Hans M, Hornung A, Dziarnowski A, Cane DE, Khosla C. Mechanistic inferences from a unique substrate channel. Proc Natl Acad Sci USA. 2013;110:15268–73.

109. Osswald C, Zipf G, Schmidt G, Maier J, Bernauer HS, Müller R, Wenzel SC. Modular construction of a functional artificial epothilone polyketide pathway. ACS Synth Biol. 2014;3:759–72.

110. Jiang M, Pfeifer BA. Improved heterologous expression of secondary metabolite clusters. ACS Synth Biol. 2017;6:995–1005.

111. Myronovskyi M, Rosenkränzer B, Nadmid S, Pujic P, Normand P, Luzhetzky A. Generation of a cluster-free Streptomyces albicus chassis strains for improved heterologous expression of secondary metabolite clusters. Metab Eng. 2018;49:316–24.

112. Rodriguez E, Ward S, Fu, Hu, Revill WP, McDaniel R, Katz L. Engineered biosynthesis of 16-membered macrolides that require methoxymalonil-ACP precursors in Streptomyces fradiae. Appl Microbiol Biotechnol. 2004;6685–91.

113. Hansen DA, Rath CM, Eissner EB, Narayan AR, Kitterendorf JD, Mortison JD, Yoon YJ, Sherman DH. Biocatalytic synthesis of pikromycin, methymycin, neomethymycin, novamethymycin, and ketomethymycin. J Am Chem Soc. 2013;135:11232–8.

114. Lowell AN, DeMars MD 2nd, Slocum ST, Yu F, Anand K, Chemler JA, Kittendorf JD, Mortison JD, Yoon YJ, Sherman DH. Chemoenzymatic total synthesis and structural diversification of tyloactone-based macrocide antibiotics through late-stage polyketide assembly, tailoring, and C-H functionalization. J Am Chem Soc. 2017;139:7913–20.

115. Pandey RP, Sohng JK. In vitro type I modular polyketide synthase catalysis for new antibiotics. Bull Korean Chem Soc. 2018;39:421–2.

116. Ji CH, Kim JP, Kang HS. Library of synthetic Streptomyces regulatory sequences for use in promoter engineering of natural product biosynthetic gene clusters. ACS Synth Biol. 2018;7:1946–55.

117. Osswald C, Zipf G, Schmidt G, Maier J, Bernauer HS, Müller R, Wenzel SC. Modular construction of a functional artificial epothilone polyketide pathway. ACS Synth Biol. 2014;3:759–72.

118. Tan Gy, Deng K, Liu X, Tao H, Chang Y, Chen J, Chen K, Sheng Z, Deng Z, Liu T. Heterologous biosynthesis of spinosad: an emics-guided large polyketide synthase gene cluster reconstitution in Streptomyces. ACS Synth Biol. 2017;6:995–1005.

119. Song MC, Kim E, Ban YH, Yoo YJ, Kim EJ, Park SR, Pandey RP, Sohng JK, Yoon YJ. Achievements and impacts of glycosylation reactions involved in natural product biosynthesis in prokaryotes. Appl Microbiol Biotechnol. 2013;97:5691–704.

120. Cao H, Chen X, Jassbi AR, Xiao J. Micrrial biotransformation of bioactive flavonoids. Biotechnol Adv. 2015;33:214–24.

121. Pandey RP, Parajuli P, Sohng JK. Metalic engineering of glycosylated polyketide biosynthesis. Emerg Top Life Sci. 2018;2:389–403.

122. Muffler K, Leipold D, Scheller MC, Haas C, Steingroewer J, Bley T, Neuhau HE, Mirata MA, Schrader J, Ulber R. Biotransformation of intermediates. Process Biochem. 2010;46:1–15.

123. Park JW, Park SR, Han AR, Ban YH, Yoo YJ, Kim EJ, Kim E, Yoon YJ. Micrrial transformation of trichostatin A to 2,3-dihydropochothastatin A. J Nat Prod. 2011;74:1272–4.
124. Lee WH, Kim MD, Jin YS, Seo JH. Engineering of NADPH regenerators in Escherichia coli for enhanced biotransformation. Appl Microbiol Biotechnol. 2013;97:7761–72.

125. Ringle M, Khatri Y, Zapp J, Hannemann F, Bernhardt R. Application of a new versatile electron transfer system for cytochrome P450-based Escherichia coli whole cell biocatalysis. Appl Microbiol Biotechnol. 2013;97:7741–54.

126. Lee WH, Kim JW, Park EH, Han NS, Kim MD, Seo JH. Effects of NADH kinase on NADPH-dependent biotransformation processes in Escherichia coli. Appl Microbiol Biotechnol. 2013;97:1561–9.

127. Pandey RP, Parajuli P, Koffas MAG, Sohng JK. Microbial production of natural and non-natural flavonoids: pathway engineering, directed evolution and systems/synthetic biology. Biotechnol Adv. 2016;34:634–62.

128. Peirú S, Rodríguez E, Menzella HG, Carney JR, Gramajo H. Metabolically engineered Escherichia coli for efficient production of glycosylated natural products. Microb Biotechnol. 2008;1:476–86.

129. Useglio M, Peirú S, Rodríguez E, Labadie GR, Carney JR, Gramajo H. TDP-L-mesoamine biosynthesis pathway elucidation and megadaltonic acid production in Escherichia coli. Appl Environ Microbiol. 2010;76:3869–77.

130. Goodman CD, Useglio M, Peirú S, Labadie GR, McCadden GJ, Rodríguez E, Gramajo H. Chembiosynthesis of new antimalarial macrolides. Antimicrob Agents Chemother. 2013;57:907–13.

131. Thibodeaux CJ, Melançon CE 3rd, Liu HW. Natural-product sugar bio-synthesis and enzymatic glycoconjugation. Angew Chem Int Ed Engl. 2008;47:9814–59.

132. Huong NL, Hoang NH, Shrestha A, Sohng JK, Yoon YJ. Production of natural products. Microb Biotechnol. 2008;1:476–86.

133. Park JW, Park SR, Han AR, Ban YH, Yoo YJ, Kim EJ, Kim E, Yoon YJ. Generation of reduced macrolide analogs by region-specific biotransformation. J Antibiot (Tokyo). 2011;64:155–7.

134. Hoang NH, Huong NL, Shrestha A, Sohng JK, Yoon YJ, Park JW. Regioselective reduced streptogramin A analogues, 5,6-dihydroxyvitaminyniamycin M1 exhibits improved potency against MRSA. Lett Appl Microbiol. 2013;57:399–8.

135. Medema MH, Kottmann R, Yilmaz P, Cummings M, Biggins JB, Blin K, Wolf T, Chevrette MG, Lu X, Schwalen CJ, Kautsar SA, et al. Microbial biotechnology in medicine and bioengineering. Front Microbiol. 2018;9:3046.

136. Robertsen HL, Weber T, Kim HU, Lee SY. Toward systems metabolic engineering of streptomycetes for secondary metabolites production on a kilogram scale promoter engineering by coselection MAGE. Nat Methods. 2012;9:591–3.

137. Nothias LF, Nothias-Espósito M, da Silva R, Wang M, Protysuk I, Zhang Z, Sarvepalli A, Leysens P, Touboul D, Costa J, Paolini J, Alexandrov T, Litauon D, Dorrestin PC. Bioactivity-based molecular networking for the discovery of drug leads in natural product bioassay-guided fractionation. J Nat Prod. 2018;81:758–67.

138. Robertsen HL, Weber T, Kim HU, Lee SY. Toward systems metabolic engineering of streptomycetes for secondary metabolites production Biotechnol J. 2018. https://doi.org/10.1002/biot.201700465.

139. Wang HH, Kim H, Cong L, Jeong J, Bang D, Church GM. Genome-scale promoter engineering for coexpression MAge. Nat Methods. 2012;9:591–3.

140. Li L, Wei K, Liu X, Wu Y, Zheng G, Chen S, Jiang W, Lu Y. Multiplexed site-specific genome engineering for overproducing bioactive secondary metabolites in actinomycetes. Metab Eng. 2017;40:80–92.

141. Doudna JA, Charpentier E. The new frontier of genome engineering with CRISPR-Cas9. Science. 2014;346:1255096.

142. Jakočiūnas T, Pedersen LE, Lies AV, Jensen MK, Keiding JD. CasPER, a method for directed evolution in genomic contexts using mutagenesis and CRISPR/Cas9. Metab Eng. 2018;48:288–96.

143. Xu M, Wright GD. Heterologous expression-facilitated natural products’ discovery in actinomycetes. J Ind Microbiol Biotechnol. 2019;46:415–31.

144. Hsu L, Hug J, Fu C, Bian X, Zhang Y, Müller R. Heterologous expression of bacterial natural product biosynthetic pathways. Nat Prod Rep. 2019. https://doi.org/10.1039/C9NP00091H.

145. Han SJ, Park SW, Park BW, Sim SJ. Selective production of epothilone B by heterologous expression of propionyl-CoA synthetase in Streptomyces cellulosum. J Microbiol Biotechnol. 2008;18:135–7.

146. Jiang H, Wang Y-Y, Ran X-X, Fan W-M, Jiang X-H, Guan W-L, et al. Improvement of natamycin production by engineering of phospho-pantetheinyl transferases in Streptomyces chartreussonis L10. Appl Environ Microbiol. 2013;79:334654.

147. Stratigopoulos G, Bate N, Cundiff E. Positive control of tylosin biosynthesis: pivotal role of TyIrp. Mol Microbiol. 2004;54:1326e34.

148. Stratigopoulos G, Cundiff E. Expression analysis of the tylosin-biosynthetic gene cluster: pivotal regulatory role of the tykQ product. Chem Biol. 2002;9:71e8.

149. Stratigopoulos G, Gandecha AR, Cundiff E. Regulation of tylosin production and morphological differentiation in Streptomyces fradiae by TyIrp, a deduced gamma-butyrolactone receptor. Mol Microbiol. 2002;45:735e44.

150. Karray F, Darbon E, Nguyen HC, Gagnat J, Pernodet JL. Regulation of the biosynthesis of the macrolide antibiotic spiramycin in Streptomyces ambofaciens. J Bacteriol. 2002;184:5813–21.

151. Zhang Y, He H, Liu H, Wang H, Wang X, Xiang W. Characterization of a pathway-specific activator of milbemycin biosynthesis and improved milbemycin production by its overexpression in Streptomyces bingchonggengsi. Microb Cell Fact. 2016;15:152.

152. Mahajan S, Gh T, Lee HC, Sohng JK. Heterologous expression of fmk1-sip and zfrr-sip in Streptomyces venezuelae for the production of pikromycin. Biotechnol Lett. 2008;30:1621–6.

153. Jung WS, Jeong SJ, Park SW, Choi CY, Park BC, Park JW, Yoon YJ. Enhanced heterologous production of desosaminyl macrolides and their hydroxylated derivatives by overexpression of the pksD regulatory gene in Streptomyces venezuelae. Appl Environ Microbiol. 2008;74:1972–9.

154. Deng Q, Zhou L, Luo M, Deng Z, Zhao C. Heterologous expression of Avemectins biosynthetic gene cluster by construction of a Bacterial Artificial Chromosome library of the producers. Synth Syst Biotechnol. 2017:2:59–64.

155. Ward SL, Hu Z, Schirmer A, Reid R, Revill WP, Reeves CD, Petrikovsky OV, Dong SQ, Katz L. Chalcomycin biosynthesis gene cluster from Streptomyces biviae: novel features of an unusual ketolide produced through expression of the cm polyketide synthase in Streptomyces fradiae. Antimicrob Agents Chemother. 2004;48:4703–12.

156. Tang L, Shah S, Chung L, Carney J, Katz L, Khosa C, Julian B. Cloning and heterologous expression of the epothilone gene cluster. Science. 2000;287:640–2.

157. Julien B, Shah S. Heterologous expression of epothilone biosynthetic genes in Myxococcus xanthus. Antimicrob Agents Chemother. 2002;46:2772–8.

158. Mutka SC, Carney JR, Liu Y, Kennedy J. Heterologous production of epothilone C and D in Escherichia coli. Biochemistry. 2006;45:1321–30.

159. Park SR, Park JW, Jung WS, Han AR, Ban Y-H, Kim EJ, Sohng JK, Sim SJ, Yoon YJ. Heterologous production of epothilone B and D in Streptomyces venezuelae. Appl Microbiol Biotechnol. 2008;78:109–17.

160. Lau J, Frykman S, Regentin R, Osu S, Tsutura H, Licari P. Optimizing the heterologous production of epothilone D in Myxococcus xanthus. Biotechnol Bioeng. 2002;78:280–8.

161. Bian X, Tang B, Yu Y, Tu Q, Gross F, Wang H, Li A, Fu Y, Shen Y, Li YZ, Stewart AF, Zhao G, Ding X, Müller R, Zhang Y. Heterologous production and yield improvement of epothilones in Burkholderiales strain DSM 7029. ACS Chem Biol. 2017;12:1805–12.
168. Zhang H, Wang Y, Wu J, Skalina K, Pfeifer BA. Complete biosynthesis of erythromycin A and designed analogs using E. coli as a heterologous host. Chem Biol. 2010;17:1232–40.
169. Volchegursky Y, Hu Z, Katz L, McDaniel R. Biosynthesis of the anti-parasitic agent megalomicin: transformation of erythromycin to megalomicin in Saccharopolyspora erythraea. Mol Microbiol. 2000;40:1045–6.
170. Jung WS, Lee SK, Hong JSJ, Park SR, Jeong SJ, Han AR, Sohng JK, Kim BG, Choi CY, Sherman DH, Yoon YJ. Heterologous expression of tylosin polyketide synthase and production of a production of a hybrid bioactive macroide in Streptomyces venezuelae. Appl Microbiol Biotechnol. 2006;72:763–9.
171. Tang L, Fu H, McDaniel R. Formation of functional heterologous complexes using subunits from the picromycin, erythromycin and oleandomycin polyketide synthases. Chem Biol. 2000;7:77–84.
172. Pyeon HR, Nah HJ, Kang SH, Choi SS, Kim ES. Heterologous expression of pikromycin biosynthetic gene cluster using Streptomyces artificial chromosome system. Microb Cell Fact. 2017;16:96.
173. Hashimoto T, Hashimoto J, Kozone I, Amagai K, Kawahara T, Takahashi S, Ikeda H, Shin-ya K. Biosynthesis of quinolidomicin, the largest known macrolide of terrestrial origin: identification and heterologous expression of a biosynthetic gene cluster over 200 kb. Org Lett. 2018. https://doi.org/10.1021/acs.orglett.8b03570.
174. Liu C, Zhang J, Lu C, Shen Y. Heterologous expression of galbonolide biosynthetic genes in Streptomyces coelicolor. Antonie Van Leeuwenhoek. 2015;107:1359–66.
175. Jones AC, Gust B, Kulik A, Heide L, Burtner MJ, Bibb MJ. Phage p1-derived artificial chromosomes facilitate heterologous expression of the FKS06 gene cluster. PLoS ONE. 2013;8:e69319.
176. Zhang B, Wang KB, Wang W, Bi SF, Mei YN, Deng XZ, Jiao RH, Tan RX, Ge HM. Discovery, biosynthesis, and heterologous production of streptoseomycin, an anti-microaerophilic bacteria macrolactone. Org Lett. 2018;20:2967–71.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.